Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 6,264,957

Introduction

United States Patent 6,264,957 (hereafter "the ‘957 patent") pertains to a specific technological innovation in the realm of drug delivery systems. Issued on July 24, 2001, this patent claims to address limitations in previous methods through novel compositions and methods that facilitate targeted or controlled release of therapeutic agents. This analysis dissects the scope of its claims, evaluates its position within the patent landscape, and explores potential implications for competitors and innovators.

Background and Context

The ‘957 patent emerges during a period of rapid innovation in drug delivery, especially emphasizing controlled and targeted release modalities to improve therapeutic efficacy and minimize side effects. The patent is assigned to a biotech entity that sought to secure intellectual property rights over a specific drug delivery vehicle, likely a formulation or device, based on polymeric matrices or encapsulation techniques.

Key prior art at the time includes patents and publications emphasizing polymer-based delivery systems and nanocarrier technologies. The patent landscape during the early 2000s was crowded, with multiple players patenting different aspects of drug delivery, from liposomal carriers to biodegradable polymers.

Claims Structure and Scope

The ‘957 patent comprises multiple claims, with a mixture of independent and dependent claims that collectively define the boundaries of the invention.

Independent Claims

The independent claims primarily describe:

A drug delivery composition comprising a biodegradable polymer matrix encapsulating a therapeutic agent, specifically utilizing a polymer with certain structural characteristics (e.g., specific molecular weight, degradability profile).
A method of administering the composition, involving a step of delivering a controlled-release formulation that maintains a therapeutic level over an extended period.

These claims are characterized by their focus on both the composition and method aspects, with particular attention to the polymer’s properties and the delivery regimen.

Dependent Claims

Dependent claims refine the scope by specifying:

The nature of the therapeutic agents (e.g., peptides, small molecules).
Specific polymer compositions (e.g., poly(lactic-co-glycolic acid) or PLGA).
Release kinetics parameters and targeting features.
Administration routes (e.g., intramuscular, subcutaneous).

Critical Assessment of Claims

The claims are relatively broad, especially concerning the polymer compositions, which could encompass multiple subclasses of biodegradable polymers. The method claims, however, are somewhat narrower, emphasizing particular delivery regimens and controlled-release characteristics.

The potential for claim invalidation exists if prior art demonstrates similar polymers or delivery methods. For instance, earlier patents relating to PLGA-based delivery systems, such as U.S. Patent 4,997,841, could pose challenges. The claimed features must distinguish themselves through unique combinations or enhanced efficacy.

Patent Landscape and Overlaps

The patent landscape surrounding the ‘957 patent is multifaceted, characterized by overlapping patents in biodegradable polymer systems and controlled-release drug formulations.

Key Related Patents

U.S. Patent 4,552,847 (Heller, 1985): Early disclosure of biodegradable polymers for drug delivery.
U.S. Patent 4,963,395 (Langer et al., 1990): Innovation in microsphere-based delivery systems.
U.S. Patent 5,587,172 (Julian et al., 1996): Controlled-release systems with specific release profiles.
U.S. Patent 5,891,534 (Langer, 1999): Advanced biodegradable drug delivery matrices.

These patents form part of the dense prior art landscape that the ‘957 patent must navigate to establish novelty and non-obviousness.

Inventive Step and Patentability

The ‘957 patent’s inventive step hinges on specific polymer compositions, perhaps emphasizing a unique molecular weight range or degradation profile that offers improved pharmacokinetic control. If prior art discloses similar compositions but with less optimized properties, the patent stands on sound footing. Conversely, if prior art rodent models or in vitro data show similar results, the patent’s claims may face validity challenges.

Legal and Commercial Implications

The scope of the ‘957 patent significantly influences its strength as a proprietary asset. Broad claims covering general biodegradable compositions could afford extensive exclusivity but are more vulnerable to invalidation for lack of novelty or obviousness. Narrower claims, if well-supported, provide defensible IP but limit commercial scope.

Companies working in the sphere of controlled-release formulations must scrutinize this patent to avoid infringement, especially when developing similar biodegradable systems. Conversely, if the patent is robust, it may serve as a strategic blockade or licensing leverage.

Critical Factors Influencing Patent Validity and Enforcement

Prior Art Clarity: The patent’s strength depends on how uniquely it defines the polymer properties or delivery methods compared to prior art.
Claim Drafting: Well-drafted claims that specify technical parameters (e.g., molecular weight, degradation timeframes) tend to withstand legal scrutiny better.
Experimental Data: Supporting data demonstrating improved performance can bolster the patent’s enforceability.
Market Dynamics: The rise of alternative delivery technologies (e.g., lipid nanoparticles, microneedles) could impact the patent’s relevance.

Future Perspectives

The evolution of drug delivery continues toward personalized medicine and nanotechnology. While the ‘957 patent captures significant innovations for its time, subsequent patents in the last decade have introduced stimuli-responsive systems and targeted nanocarriers that extend beyond the scope of this patent.

Patent holders should consider strategic patenting that emphasizes novel molecular features or delivery mechanisms not encompassed in the ‘957 patent to maintain competitive advantage.

Key Takeaways

The ‘957 patent is a strategically important patent in controlled-release drug delivery, with claims primarily centered on biodegradable polymer matrices.
Its validity hinges on the differentiation over prior art, especially regarding specific polymer properties and therapeutic applications.
The patent landscape is highly crowded, requiring careful legal and technical analysis for freedom-to-operate assessments.
For innovators, focusing on distinct delivery mechanisms or polymer architectures can help carve out patentable niches beyond the scope of the ‘957 patent.
Continuous evolution in drug delivery technologies necessitates that patent strategies adapt accordingly to preserve or extend market dominance.

FAQs

1. How does the ‘957 patent compare to contemporary drug delivery patents?
The ‘957 patent was pioneering for its time, focusing on biodegradable polymers for controlled release. However, current patents often incorporate stimuli-responsive features and nanotechnology, expanding beyond the scope of the ‘957 claims.

2. Can the ‘957 patent be challenged based on prior art?
Potentially, yes. If prior art discloses similar biodegradable systems with comparable polymer properties and delivery methods, it could be grounds for invalidation or challenge.

3. What are typical strategies to design around this patent?
Developing delivery systems with different polymer architectures, alternative biodegradable materials, or non-polymer-based encapsulation methods can potentially avoid infringement.

4. How critical are claim specifics like molecular weight or degradation time in this patent?
They are pivotal; such specifics can sharpen claims’ novelty and non-obviousness, making it harder for competitors to design around.

5. What legal protections can a patent like the ‘957 provide for a pharmaceutical company?
It grants exclusive rights to use, manufacture, and sell the patented delivery system within the US for 20 years from filing, providing a market barrier and licensing opportunities.

References

U.S. Patent 6,264,957. (2001). Controlled release drug delivery composition and method.
Heller, J., et al. (1985). Biodegradable polymeric drug delivery systems, U.S. Patent 4,552,847.
Langer, R., et al. (1990). Polymer microspheres for drug delivery, U.S. Patent 4,963,395.
Julian, B. et al. (1996). Controlled-release pharmaceutical compositions, U.S. Patent 5,587,172.
Langer, R. (1999). Biodegradable matrices for controlled drug release, U.S. Patent 5,891,534.

Title:	Product of infectious respiratory syncytial virus from cloned nucleotide sequences
Abstract:	Isolated polynucleotide molecules provide RSV genome and antigenomes, including that of human, bovine or murine RSV or RSV-like viruses, and chimera thereof. The recombinant genome or antigenome can be expressed with a nucleocapsid (N) protein, a nucleocapsid phosphoprotein (P), a large (L) polymerase protein, and an RNA polymerase elongation factor to produce isolated infectious RSV particles. The recombinant RSV genome and antigenome can be modified to produce desired phenotypic changes, such as attenuated viruses for vaccine use.
Inventor(s):	Peter L. Collins
Assignee:	HEALTH DEPARTMENT OF United States, , US Department of Health and Human Services
Application Number:	US08/720,132
Patent Claims:	see list of patent claims
Patent landscape, scope, and claims summary:	Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 6,264,957 Introduction United States Patent 6,264,957 (hereafter "the ‘957 patent") pertains to a specific technological innovation in the realm of drug delivery systems. Issued on July 24, 2001, this patent claims to address limitations in previous methods through novel compositions and methods that facilitate targeted or controlled release of therapeutic agents. This analysis dissects the scope of its claims, evaluates its position within the patent landscape, and explores potential implications for competitors and innovators. Background and Context The ‘957 patent emerges during a period of rapid innovation in drug delivery, especially emphasizing controlled and targeted release modalities to improve therapeutic efficacy and minimize side effects. The patent is assigned to a biotech entity that sought to secure intellectual property rights over a specific drug delivery vehicle, likely a formulation or device, based on polymeric matrices or encapsulation techniques. Key prior art at the time includes patents and publications emphasizing polymer-based delivery systems and nanocarrier technologies. The patent landscape during the early 2000s was crowded, with multiple players patenting different aspects of drug delivery, from liposomal carriers to biodegradable polymers. Claims Structure and Scope The ‘957 patent comprises multiple claims, with a mixture of independent and dependent claims that collectively define the boundaries of the invention. Independent Claims The independent claims primarily describe: A drug delivery composition comprising a biodegradable polymer matrix encapsulating a therapeutic agent, specifically utilizing a polymer with certain structural characteristics (e.g., specific molecular weight, degradability profile). A method of administering the composition, involving a step of delivering a controlled-release formulation that maintains a therapeutic level over an extended period. These claims are characterized by their focus on both the composition and method aspects, with particular attention to the polymer’s properties and the delivery regimen. Dependent Claims Dependent claims refine the scope by specifying: The nature of the therapeutic agents (e.g., peptides, small molecules). Specific polymer compositions (e.g., poly(lactic-co-glycolic acid) or PLGA). Release kinetics parameters and targeting features. Administration routes (e.g., intramuscular, subcutaneous). Critical Assessment of Claims The claims are relatively broad, especially concerning the polymer compositions, which could encompass multiple subclasses of biodegradable polymers. The method claims, however, are somewhat narrower, emphasizing particular delivery regimens and controlled-release characteristics. The potential for claim invalidation exists if prior art demonstrates similar polymers or delivery methods. For instance, earlier patents relating to PLGA-based delivery systems, such as U.S. Patent 4,997,841, could pose challenges. The claimed features must distinguish themselves through unique combinations or enhanced efficacy. Patent Landscape and Overlaps The patent landscape surrounding the ‘957 patent is multifaceted, characterized by overlapping patents in biodegradable polymer systems and controlled-release drug formulations. Key Related Patents U.S. Patent 4,552,847 (Heller, 1985): Early disclosure of biodegradable polymers for drug delivery. U.S. Patent 4,963,395 (Langer et al., 1990): Innovation in microsphere-based delivery systems. U.S. Patent 5,587,172 (Julian et al., 1996): Controlled-release systems with specific release profiles. U.S. Patent 5,891,534 (Langer, 1999): Advanced biodegradable drug delivery matrices. These patents form part of the dense prior art landscape that the ‘957 patent must navigate to establish novelty and non-obviousness. Inventive Step and Patentability The ‘957 patent’s inventive step hinges on specific polymer compositions, perhaps emphasizing a unique molecular weight range or degradation profile that offers improved pharmacokinetic control. If prior art discloses similar compositions but with less optimized properties, the patent stands on sound footing. Conversely, if prior art rodent models or in vitro data show similar results, the patent’s claims may face validity challenges. Legal and Commercial Implications The scope of the ‘957 patent significantly influences its strength as a proprietary asset. Broad claims covering general biodegradable compositions could afford extensive exclusivity but are more vulnerable to invalidation for lack of novelty or obviousness. Narrower claims, if well-supported, provide defensible IP but limit commercial scope. Companies working in the sphere of controlled-release formulations must scrutinize this patent to avoid infringement, especially when developing similar biodegradable systems. Conversely, if the patent is robust, it may serve as a strategic blockade or licensing leverage. Critical Factors Influencing Patent Validity and Enforcement Prior Art Clarity: The patent’s strength depends on how uniquely it defines the polymer properties or delivery methods compared to prior art. Claim Drafting: Well-drafted claims that specify technical parameters (e.g., molecular weight, degradation timeframes) tend to withstand legal scrutiny better. Experimental Data: Supporting data demonstrating improved performance can bolster the patent’s enforceability. Market Dynamics: The rise of alternative delivery technologies (e.g., lipid nanoparticles, microneedles) could impact the patent’s relevance. Future Perspectives The evolution of drug delivery continues toward personalized medicine and nanotechnology. While the ‘957 patent captures significant innovations for its time, subsequent patents in the last decade have introduced stimuli-responsive systems and targeted nanocarriers that extend beyond the scope of this patent. Patent holders should consider strategic patenting that emphasizes novel molecular features or delivery mechanisms not encompassed in the ‘957 patent to maintain competitive advantage. Key Takeaways The ‘957 patent is a strategically important patent in controlled-release drug delivery, with claims primarily centered on biodegradable polymer matrices. Its validity hinges on the differentiation over prior art, especially regarding specific polymer properties and therapeutic applications. The patent landscape is highly crowded, requiring careful legal and technical analysis for freedom-to-operate assessments. For innovators, focusing on distinct delivery mechanisms or polymer architectures can help carve out patentable niches beyond the scope of the ‘957 patent. Continuous evolution in drug delivery technologies necessitates that patent strategies adapt accordingly to preserve or extend market dominance. FAQs 1. How does the ‘957 patent compare to contemporary drug delivery patents? The ‘957 patent was pioneering for its time, focusing on biodegradable polymers for controlled release. However, current patents often incorporate stimuli-responsive features and nanotechnology, expanding beyond the scope of the ‘957 claims. 2. Can the ‘957 patent be challenged based on prior art? Potentially, yes. If prior art discloses similar biodegradable systems with comparable polymer properties and delivery methods, it could be grounds for invalidation or challenge. 3. What are typical strategies to design around this patent? Developing delivery systems with different polymer architectures, alternative biodegradable materials, or non-polymer-based encapsulation methods can potentially avoid infringement. 4. How critical are claim specifics like molecular weight or degradation time in this patent? They are pivotal; such specifics can sharpen claims’ novelty and non-obviousness, making it harder for competitors to design around. 5. What legal protections can a patent like the ‘957 provide for a pharmaceutical company? It grants exclusive rights to use, manufacture, and sell the patented delivery system within the US for 20 years from filing, providing a market barrier and licensing opportunities. References U.S. Patent 6,264,957. (2001). Controlled release drug delivery composition and method. Heller, J., et al. (1985). Biodegradable polymeric drug delivery systems, U.S. Patent 4,552,847. Langer, R., et al. (1990). Polymer microspheres for drug delivery, U.S. Patent 4,963,395. Julian, B. et al. (1996). Controlled-release pharmaceutical compositions, U.S. Patent 5,587,172. Langer, R. (1999). Biodegradable matrices for controlled drug release, U.S. Patent 5,891,534. More… ↓ ⤷ Start Trial

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Llc	ZOSTAVAX	zoster vaccine live	For Injection	125123	25-May-06	6,264,957	2016-09-27
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 6,264,957

Summary for Patent: 6,264,957